Sonoma Pharmaceuticals, Inc. Logo

Sonoma Pharmaceuticals, Inc.

Develops products based on patented, stabilized hypochlorous acid (HOCl) technology.

SNOA | US

Overview

Corporate Details

ISIN(s):
US83558L2043
LEI:
Country:
United States of America
Address:
5445 CONESTOGA COURT, SUITE 150, 80301 BOULDER

Description

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-06-21 19:05 English DOC 7.0 KB
2024-06-21 19:05 English DOC 7.0 KB
2024-06-21 18:56
PRE 14A
English DOC 582.9 KB
2024-06-17 18:21
S-8
English DOC 32.1 KB
2024-06-17 18:13
FORM 10-K FOR 3/31/24
English DOC 1.9 MB
2024-04-09 09:30
FORM 8-K
English DOC 7.9 MB
2024-04-02 09:30
CURRENT REPORT
English DOC 8.5 MB
2024-03-22 17:30
CURRENT REPORT
English DOC 81.3 KB
2024-03-08 17:29
CURRENT REPORT
English DOC 137.6 KB
2024-03-08 17:27
PROSPECTUS SUPPLEMENT
English DOC 115.9 KB
2024-02-08 17:01
FORM 10-Q FOR DEC 2023
English DOC 1000.2 KB
2024-01-10 08:30
CURRENT REPORT
English DOC 5.1 MB
2024-01-09 17:47
CURRENT REPORT
English DOC 120.7 KB
2023-12-29 18:26 English DOC 7.2 KB
2023-12-29 18:25 English DOC 7.3 KB

Automate Your Workflow. Get a real-time feed of all Sonoma Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sonoma Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sonoma Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.